Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HITCLIF
2023-504943-15-00Phase 2Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of imipramine in colon cancer, rectal cancer and triple-negative breast cancer (TNBC), sponsored by Fundación para la Formación e Investigación Sanitaria. Planned start Aug 2023; status: authorised.
02
Drugs
imipramine
03
Conditions
colon cancerrectal cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-504943-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504943-15-00.